Resverlogix Corp. (OTC: RVXCF) is an epigenetics company, creating small molecule therapeutics for BET inhibition. The company is currently developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. It is the only selective BET bromodomain inhibitor in clinical trials. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. For more information, visit company’s website at www.resverlogix.com.